Video description: ApoB versus LDL for heart attack risk, with cited studies
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedThe description says ApoB counts particles that enter artery walls and start plaque, and that large studies found ApoB predicted heart attacks better than LDL, including in statin-treated people whose LDL was at goal. It cites a 23% reduction in heart attacks with bempedoic acid and a modest ApoB effect from oat beta-glucan. [1]
The description says LDL measures blood cholesterol amount, while ApoB counts particles that enter artery walls and start plaque. [1]
The description cites a Copenhagen study of 13,015 statin-treated patients in which ApoB and non-HDL cholesterol, but not LDL cholesterol alone, tracked residual heart attack and mortality risk. [1]
The description cites a 2016 meta-analysis of 58 trials in which about 3.5 g per day of oat beta-glucan lowered ApoB by 2.3% and LDL by 4.2%. [1]
ApoB particles versus LDL cholesterol amount
According to the description, LDL measures how much cholesterol is in the blood, while ApoB counts the particles that actually get into artery walls and start plaque. The creator says this is why LDL can look “normal” while heart attack risk is high. The description attributes this framing to the creator, an emergency medicine physician. [1]
Cited studies on ApoB prediction and bempedoic acid
The description lists Marston et al. 2022 in JAMA Cardiology, where ApoB was the only lipid marker independently associated with heart attack risk after adjustment. It also lists Johannesen et al. 2021 in JACC, a Copenhagen population study of 13,015 statin-treated patients, where ApoB and non-HDL cholesterol tracked residual heart attack and mortality risk but LDL cholesterol alone did not. Nissen et al. 2023 in NEJM, the CLEAR Outcomes trial with over 14,000 statin-intolerant patients, is said to show bempedoic acid cut major cardiovascular events by 13% and heart attacks by 23%. [1]
Oat beta-glucan effect and description-only scope
The description cites a 2016 meta-analysis in the British Journal of Nutrition of 58 trials with about 4,000 participants: about 3.5 g per day of oat beta-glucan lowered ApoB by 2.3% and LDL by 4.2%, described as a real but modest effect. It also mentions an ACC/AHA 2026 dyslipidemia guideline recommending ApoB testing for residual risk in higher-risk patients. These are the creator’s cited sources; the video and transcript were not reviewed. [1]
Context & limits
Only the video description was available; the video and transcript were not reviewed. Study details, designs and numbers come from the creator’s description and cited list, not from independent checking. The description also promotes the creator’s practice and includes a personal disclaimer.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
LDL measures how much cholesterol is in
13,015 statin-treated patients
58 trials, ~4,000 participants
About this video
Creator description · original textText language: American English
Dr. Joanette MD · 14 min · Source published: 2026-10-12
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.